Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | HTR5A | P47898 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7341749 | 0.91 | MEN1 (0.48) | DAOMEN1KMT2AMAPTMAPK1 | |
| SCHEMBL8350404 | 0.86 | GNRHR (0.52) | MEN1KMT2AMAPTMAPK1POLB | |
| SCHEMBL7333842 | 0.73 | L3MBTL1 (0.54) | MEN1KMT2AMAPTMAPK1POLB | |
| SCHEMBL8136894 | 0.73 | GNRHR (0.66) | MEN1KMT2AMAPTMAPK1POLB | |
| SCHEMBL7342785 | 0.73 | DAO (0.47) | DAOMEN1KMT2AMAPTMAPK1 | |
| Hydrochloric Acid SCHEMBL8133412 | 0.72 | GNRHR (0.64) | MEN1KMT2AMAPTMAPK1POLB | |
| SCHEMBL7246660 | 0.71 | DRD2 (0.64) | MEN1KMT2AMAPTL3MBTL1ABCB1 | |
| SCHEMBL1135811 | 0.70 | GRIN2D (0.46) | DAOMEN1KMT2AATMKDM4E | |
| SCHEMBL1135620 | 0.70 | KDM4E (0.47) | MEN1KMT2AMAPK1SMN1; SMN2KDM4E | |
| SCHEMBL7253798 | 0.70 | L3MBTL1 (0.71) | MEN1KMT2AMAPTPOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070117788-A1 | Combination of a dopamine D2-receptor agonist and tiotropium or a derivative therof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-05-24 | — | — | US | disclosed |
| US-20070117788-A1 | Combination of a dopamine D2-receptor agonist and tiotropium or a derivative therof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-05-24 | — | — | US | disclosed |
| EP-0963372-A1 | 5-AMINOALKOXY-1,4-DIHYDROQUINOXALINE-2,3-DIONES BEING DOPAMINE AGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-12-15 | — | — | EP | disclosed |
| WO-1998035948-A1 | 5-AMINOALKOXY-1,4-DIHYDROQUINOXALINE-2,3-DIONES BEING DOPAMINE AGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117788-A1 | Combination of a dopamine D2-receptor agonist and tiotropium or a derivative therof for treating obstructive airways and other inflammatory diseases | CHRM2, ADRB2, CHRM3 | DAO 1132/4885MEN1 3175/4885KMT2A 3733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.